Edmonton, Alberta, CANADA, February 2, 2026 -- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, and 48Hour Discovery,...
New Research Led by 48Hour Discovery Scientists Enables Efficient Conversion of Macrocycles into Bicyclic Peptides April 22, 2025 - A...
Empowering Local Innovation: 48Hour Discovery Receives $530k from the Edmonton Edge Fund to Scale Drug Discovery Business May 8, 2024...
Local biotech 48Hour Discovery, in partnership with Dr. Frank Wuest from the University of Alberta, secures vital funding to advance...
Pioneering Peptide Discovery for a Healthy World
